HTG Molecular Diagnostics (HTGM) Tops Q3 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Survey Shows Low Awareness and Purchase Intent on HTG Molecular Diagnostics (HTGM); Leerink Partners Cuts Price Target to $10
November 13, 2015 10:12 AM ESTLeerink Partners reiterates an Outperform rating on HTG Molecular Diagnostics (NASDAQ: HTGM), and cut the price target to $10.00 (from $18.00), following the company's 3Q15 earnings report. HTGM reported Q3 revenue of $1M, in line with the Street expectation. However, Survey work suggests awareness of its... More
